Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 6Unknown 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 24Carcinoma, Renal Cell 15Carcinoma, Non-Small-Cell Lung 15Neoplasm Metastasis 12Urinary Bladder Neoplasms 6Sarcoma 6Prostatic Neoplasms 6Lung Neoplasms 6Pancreatic Neoplasms 5Neoplasms 5Kidney Neoplasms 5Ovarian Neoplasms 4Glioblastoma 4Carcinoma, Transitional Cell 4Uveal Melanoma 3Small Cell Lung Carcinoma 3Myelodysplastic Syndromes 3Mesothelioma 3Histiocytoma, Malignant Fibrous 3Colorectal Neoplasms 3Chordoma 3Carcinoma, Neuroendocrine 3Carcinoma, Merkel Cell 3Breast Neoplasms 3Brain Neoplasms 3Urogenital Neoplasms 2Urethral Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2

Interventions

Oxaliplatin 21pembrolizumab 17Capecitabine 15Nivolumab 13Paclitaxel 12Fluorouracil 12Leucovorin 11Docetaxel 10atezolizumab 7Trastuzumab 7tislelizumab 5Ramucirumab 5durvalumab 4Standard of Care 4Magnetic Resonance Spectroscopy 4Irinotecan 4Cisplatin 4Carboplatin 4zolbetuximab 3zimberelimab 3apatinib 3Specimen Handling 3S 1 (combination) 3Gemcitabine 3Bevacizumab 3trifluridine tipiracil drug combination 2tremelimumab 2trastuzumab deruxtecan 2relatlimab 2osimertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Stomach Neoplasms × Ipilimumab × Clear all
NCT05144854 2024-09-05

A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Ono Pharmaceutical Co., Ltd.

Phase 3 Active not recruiting
626 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡